Mopidralazine hydrochloride
Mopidralazine hydrochloride (MDL-899) (Compound 30) is an orally active antihypertensive agent. Mopidralazine hydrochloride significantly reduces systolic blood pressure (ED50 = 1.94 mg/kg) in spontaneously hypertensive rats models. Mopidralazine hydrochloride has a slower onset of action but a longer duration of action and has a significantly smaller effect on increasing heart rate in canine model of renal hypertension. Mopidralazine hydrochloride can be used for the research of hypertension.
For research use only. We do not sell to patients.
- CAS No.: 86703-02-8
- Formula: C14H20ClN5O
- Molecular Weight:309.79
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Chemical Information
-
CAS No. 86703-02-8
-
Molecular Weight 309.79
-
Formula C14H20ClN5O
-
SMILES
CC1=CC=C(C)N1NC2=NN=C(N3CCOCC3)C=C2.Cl
-
Synonyms
MDL-899
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)